Its seems that intensive crosstalk and by-pass reaction between the RAS-RAF-ERK-MAPK pathway and the PI3K-AKT-mTor pathway requires an inhibition of both arms to be really efficient, which was seen in different approaches in CRC [52] and also in non-small cell lung cancer cell (NSCLC) xenograft tumors treated with small molecules [53]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.